# Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

> **NCT03391934** · PHASE3 · UNKNOWN · sponsor: **Cinnagen** · enrollment: 234 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab + FOLFIRI

## Key facts

- **NCT ID:** NCT03391934
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-20
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-02-01
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03391934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03391934, "Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03391934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*